Search

Your search keyword '"Carcinoma 256, Walker metabolism"' showing total 703 results

Search Constraints

Start Over You searched for: Descriptor "Carcinoma 256, Walker metabolism" Remove constraint Descriptor: "Carcinoma 256, Walker metabolism"
703 results on '"Carcinoma 256, Walker metabolism"'

Search Results

1. Fish Oil Diet during Pre-mating, Gestation, and Lactation in Adult Offspring Rats on Cancer Cachexia Prevention.

2. Laser-photobiomodulation on experimental cancer pain model in Walker Tumor-256.

3. Structural changes of serum albumin in response to oxidative stress caused by Walker-256 carcinosarcoma growth.

4. Creatine supplementation in Walker-256 tumor-bearing rats prevents skeletal muscle atrophy by attenuating systemic inflammation and protein degradation signaling.

5. Leucine-rich diet induces a shift in tumour metabolism from glycolytic towards oxidative phosphorylation, reducing glucose consumption and metastasis in Walker-256 tumour-bearing rats.

6. Dynamic urinary proteomic analysis in a Walker 256 intracerebral tumor model.

7. The influence of lactoferrin on elemental homeostasis and activity of metal-containing enzymes in rats with Walker-256 carcinosarcoma.

8. Morphological features of doxorubicin-resistant Walker 256 carcinosarcoma and response of mast cells.

9. Metabolic effects of Hedyotis diffusa on rats bearing Walker 256 tumor revealed by NMR-based metabolomics.

10. Influence of vasomodulators and tumor transplantation on the disposition of 5-fluorouracil after application to the liver surface in rats.

11. Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats.

12. Ruthenium complex exerts antineoplastic effects that are mediated by oxidative stress without inducing toxicity in Walker-256 tumor-bearing rats.

13. L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats.

14. Normalizing GDNF expression in the spinal cord alleviates cutaneous hyperalgesia but not ongoing pain in a rat model of bone cancer pain.

15. Pharmacokinetic/pharmacodynamic modeling of etoposide tumor growth inhibitory effect in Walker-256 tumor-bearing rat model using free intratumoral drug concentrations.

16. Resistance exercise prevents impaired homocysteine metabolism and hepatic redox capacity in Walker-256 tumor-bearing male Wistar rats.

17. Connexin 43 Mediates CXCL12 Production from Spinal Dorsal Horn to Maintain Bone Cancer Pain in Rats.

18. Low-Dose Cannabinoid Type 2 Receptor Agonist Attenuates Tolerance to Repeated Morphine Administration via Regulating μ-Opioid Receptor Expression in Walker 256 Tumor-Bearing Rats.

19. Lamellipodia and Membrane Blebs Drive Efficient Electrotactic Migration of Rat Walker Carcinosarcoma Cells WC 256.

20. Remodulating effect of doxorubicin on the state of iron-containing proteins, and redox characteristics of tumor with allowance for its sensitivity to cytostatic agents.

21. Acidosis Promotes Metastasis Formation by Enhancing Tumor Cell Motility.

22. Walker 256 tumor-bearing rats demonstrate altered interstitial cells of Cajal. Effects on ICC in the Walker 256 tumor model.

23. Fish oil administration mediates apoptosis of Walker 256 tumor cells by modulation of p53, Bcl-2, caspase-7 and caspase-3 protein expression.

24. Biochemical action of new complexes of ruthenium with quinolones as potential antitumor agents.

25. Regression of Walker 256 carcinosarcoma in vasopressin-deficient Brattleboro rats is accompanied by a changed laminin pattern.

26. METALLOPROTEINS DURING DEVELOPMENT OF WALKER-256 CARCINOSARCOMA RESISTANT PHENOTYPE.

27. Expression of vascular endothelial growth factor (VEGF-A) in rat mandibular salivary gland during paraneoplastic process and treatment with cyclophosphamide and melatonin.

28. Effects of celecoxib and ibuprofen on metabolic disorders induced by Walker-256 tumor in rats.

29. The role of microtubules in electrotaxis of rat Walker carcinosarcoma WC256 cells.

30. Increased nitric oxide levels in cerebellum of cachectic rats with Walker 256 solid tumor.

31. Changes in lipid metabolism during Walker 256 tumor growth and the therapeutic effect of hyperthermia.

32. Involvement of protease-activated receptor 2 in nociceptive behavior in a rat model of bone cancer.

33. Leucine-rich diet supplementation modulates foetal muscle protein metabolism impaired by Walker-256 tumour.

34. Protective effect of metformin against walker 256 tumor growth is not dependent on metabolism improvement.

35. Optimal treatment opportunity for mTHPC-mediated photodynamic therapy of liver cancer.

36. Antitumor and anti-cachectic effects of shark liver oil and fish oil: comparison between independent or associative chronic supplementation in Walker 256 tumor-bearing rats.

37. Leucine modulates the effect of Walker factor, a proteolysis-inducing factor-like protein from Walker tumours, on gene expression and cellular activity in C2C12 myotubes.

38. Combination of injection volume calibration by creatinine and MS signals' normalization to overcome urine variability in LC-MS-based metabolomics studies.

39. Tumor growth reduction is regulated at the gene level in Walker 256 tumor-bearing rats supplemented with fish oil rich in EPA and DHA.

40. Changes in liver gluconeogenesis during the development of Walker-256 tumour in rats.

41. Uncaria tomentosa exerts extensive anti-neoplastic effects against the Walker-256 tumour by modulating oxidative stress and not by alkaloid activity.

42. [Expression of the RT1A molecule of the class I major histocompatibility complex in a Walker 256 tumor after transplantation into Brattleboro rats with a genetic defect of arginine-vasopressin synthesis].

43. Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion.

44. [Aitongxiao recipe regulated survivin and Bcl- 2 in rats' transplanted hepatoma carcinoma cell].

45. Decreased response to cAMP in the glucose and glycogen catabolism in perfused livers of Walker-256 tumor-bearing rats.

46. Participation of the NO/cGMP/K+ATP pathway in the antinociception induced by Walker tumor bearing in rats.

47. Changes in blood metabolic parameters during the development of Walker-256 tumour-induced cachexia in rats are not caused by decreased food intake.

48. P2Y1 purinoceptor inhibition reduces extracellular signal-regulated protein kinase 1/2 phosphorylation in spinal cord and dorsal root ganglia: implications for cancer-induced bone pain.

49. Naringin inhibits tumor growth and reduces interleukin-6 and tumor necrosis factor α levels in rats with Walker 256 carcinosarcoma.

50. Effect of malignant ascites on antioxidative potency of two tumoral cells-induced bone metastases: Walker 256/B and MatLyLu.

Catalog

Books, media, physical & digital resources